Edge Rewrite
everything Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a22a1fb7ecba845c

Jump to content

TG103

Add links
From Wikipedia, the free encyclopedia

TG103 is an experimental GLP-1 receptor agonist and Fc fusion protein combination, developed by CSPC Pharmaceutical Group.[1]

References

[edit]
  1. ↑ Jin, Jiangli; Cui, Gang; Mi, Na; Wu, Wei; Zhang, Xin; Xiao, Chunyan; Wang, Jing; Qiu, Xueying; Han, Mai; Li, Ziyan; Wang, Lei; Lu, Tong; Niu, Huikun; Wu, Zhaoxi; Li, Jintong (1 June 2023). "Safety, pharmacokinetics, and pharmacodynamics of TG103, a novel long-acting GLP-1/Fc fusion protein after a single ascending dose in Chinese healthy subjects". European Journal of Pharmaceutical Sciences. 185 106448. doi:10.1016/j.ejps.2023.106448. PMID 37062422. S2CID 258166248.
Retrieved from "https://en.wikipedia.org/w/index.php?title=TG103&oldid=1315291834"